176 related articles for article (PubMed ID: 29947576)
21. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
22. Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma.
Wood SY; Ryan JC; Clair AG; George DJ
Future Oncol; 2020 Feb; 16(4):39-47. PubMed ID: 31922424
[TBL] [Abstract][Full Text] [Related]
23. Two Childhood Pheochromocytoma Cases due to von Hippel-Lindau Disease, One Associated with Pancreatic Neuroendocrine Tumor: A Very Rare Manifestation.
Dağdeviren Çakır A; Turan H; Aykut A; Durmaz A; Ercan O; Evliyaoğlu O
J Clin Res Pediatr Endocrinol; 2018 Jun; 10(2):179-182. PubMed ID: 29022557
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib treatment for multifocal renal cell carcinoma (RCC) and pancreatic neuroendocrine tumor (NET) in patient with Von Hippel-Lindau disease. Case Report.
Babinska A; Studniarek M; Świątkowska-Stodulska R; Sworczak K
Neuro Endocrinol Lett; 2015 Dec; 36(6):517-20. PubMed ID: 26812297
[TBL] [Abstract][Full Text] [Related]
25. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.
Prowse AH; Webster AR; Richards FM; Richard S; Olschwang S; Resche F; Affara NA; Maher ER
Am J Hum Genet; 1997 Apr; 60(4):765-71. PubMed ID: 9106522
[TBL] [Abstract][Full Text] [Related]
26. Von Hippel-Lindau and myotonic dystrophy of Steinert along with pancreatic neuroendocrine tumor and renal clear cell carcinomal neoplasm: Case report and review of the literature.
Addeo A; Bini R; Viora T; Bonaccorsi L; Leli R
Int J Surg Case Rep; 2013; 4(8):648-50. PubMed ID: 23774333
[TBL] [Abstract][Full Text] [Related]
27. Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.
Kobayashi A; Takahashi M; Imai H; Akiyama S; Sugiyama S; Komine K; Saijo K; Takahashi M; Takahashi S; Shirota H; Sato N; Fujishima F; Shuin T; Shimodaira H; Ishioka C
Intern Med; 2016; 55(6):629-34. PubMed ID: 26984080
[TBL] [Abstract][Full Text] [Related]
28. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
29. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis.
Lott ST; Chandler DS; Curley SA; Foster CJ; El-Naggar A; Frazier M; Strong LC; Lovell M; Killary AM
Cancer Res; 2002 Apr; 62(7):1952-5. PubMed ID: 11929809
[TBL] [Abstract][Full Text] [Related]
30. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
[TBL] [Abstract][Full Text] [Related]
31. Genotype-phenotype correlations, and retinal function and structure in von Hippel-Lindau disease.
Wittström E; Nordling M; Andréasson S
Ophthalmic Genet; 2014 Jun; 35(2):91-106. PubMed ID: 24555745
[TBL] [Abstract][Full Text] [Related]
32. Genetic study of a large Chinese kindred with von Hippel-Lindau disease.
Huang YR; Zhang J; Wang JD; Fan XD
Chin Med J (Engl); 2004 Apr; 117(4):552-7. PubMed ID: 15109448
[TBL] [Abstract][Full Text] [Related]
33. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.
Louise M Binderup M; Smerdel M; Borgwadt L; Beck Nielsen SS; Madsen MG; Møller HU; Kiilgaard JF; Friis-Hansen L; Harbud V; Cortnum S; Owen H; Gimsing S; Friis Juhl HA; Munthe S; Geilswijk M; Rasmussen ÅK; Møldrup U; Graumann O; Donskov F; Grønbæk H; Stausbøl-Grøn B; Schaffalitzky de Muckadell O; Knigge U; Dam G; Wadt KA; Bøgeskov L; Bagi P; Lund L; Stochholm K; Ousager LB; Sunde L
Eur J Med Genet; 2022 Aug; 65(8):104538. PubMed ID: 35709961
[TBL] [Abstract][Full Text] [Related]
34. The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?
Gyawali B; Goldstein DA
JAMA Oncol; 2018 May; 4(5):623-624. PubMed ID: 29522146
[No Abstract] [Full Text] [Related]
35. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas.
Dannenberg H; De Krijger RR; van der Harst E; Abbou M; IJzendoorn Y; Komminoth P; Dinjens WN
Int J Cancer; 2003 Jun; 105(2):190-5. PubMed ID: 12673678
[TBL] [Abstract][Full Text] [Related]
36. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
37. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study.
Kano H; Shuto T; Iwai Y; Sheehan J; Yamamoto M; McBride HL; Sato M; Serizawa T; Yomo S; Moriki A; Kohda Y; Young B; Suzuki S; Kenai H; Duma C; Kikuchi Y; Mathieu D; Akabane A; Nagano O; Kondziolka D; Lunsford LD
J Neurosurg; 2015 Jun; 122(6):1469-78. PubMed ID: 25816088
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients.
Salama Y; Albanyan S; Szybowska M; Bullivant G; Gallinger B; Giles RH; Asa S; Badduke C; Chiorean A; Druker H; Ezzat S; Hannah-Shmouni F; Hernandez KG; Inglese C; Jani P; Kaur Y; Krema H; Krimus L; Laperriere N; Lichner Z; Mete O; Sit M; Zadeh G; Jewett MAS; Malkin D; Stockley T; Wasserman JD; Xu W; Schachter NF; Kim RH
Clin Genet; 2019 Nov; 96(5):461-467. PubMed ID: 31368132
[TBL] [Abstract][Full Text] [Related]
40. The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients.
Ma K; Hong B; Zhou J; Gong Y; Wang J; Liu S; Peng X; Zhou B; Zhang J; Xie H; Zhang K; Li L; Cai D; Wang Z; Cai L; Gong K
Front Oncol; 2019; 9():1122. PubMed ID: 31737565
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
